Managing aggressive behavior in patients with obsessive-compulsive disorder and borderline personality disorder

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 15, 1999, Pages 38-44

  Hollander, Eric ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; ALPRAZOLAM; ANTICONVULSIVE AGENT; BUSPIRONE; CARBAMAZEPINE; FLUOXETINE; HALOPERIDOL; LITHIUM; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PHENELZINE; PHENYTOIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIOTIXENE; TRANYLCYPROMINE; TRIFLUOPERAZINE; VALPROATE SEMISODIUM;

AGGRESSION; ANTISOCIAL BEHAVIOR; ARTICLE; BORDERLINE STATE; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; COMPULSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; IMPULSIVENESS; MALE; MOOD; OBSESSION; PERSONALITY DISORDER; PRIORITY JOURNAL;

AGGRESSION; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; BORDERLINE PERSONALITY DISORDER; CLINICAL TRIALS; COMORBIDITY; HUMANS; MENTAL DISORDERS; MONOAMINE OXIDASE INHIBITORS; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0032838652     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Karno M, Golding JM, Sorenson SB, et al. The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry 1988; 45:1094-1099
2. Hollander E, Greenwald S, Neville D, et al. Uncomplicated and comorbid obsessive-compulsive disorder in an epidemiologic sample. Depression Anxiety 1996;4:111-119
3. Hollander E. Introduction: obsessive-compulsive disorder: the hidden epidemic. J Clin Psychiatry 1997;58(suppl 12):3-6
4. Hollander E, Kwon JH, Stein DJ, et al. Obsessive-compulsive and spectrum disorders: overview and quality of life issues. J Clin Psychiatry 1996; 57(suppl 8):3-6
5. Stein DJ, Hollander E, DeCaria CM, et al. m-Clorophenylpiperazine challenge in borderline personality disorder: relationship of neuroendocrine response, behavioral response, and clinical measures. Biol Psychiatry 1996; 40:508-513
6. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 1998;94:127-152
7. Cyr M, Brown CS. Current drug therapy recommendations for the treatment of attention deficit hyperactivity disorder. Drugs 1998;56:215-223
8. Licht RW. Drug treatment of mania: a critical review. Acta Psychiatr Scand 1998;97:387-397
9. Prichep LS, Mas F, Hollander E, et al. Quantitative electroencephalographic subtyping of obsessive-compulsive disorder. Psychiatry Res 1993; 50:25-32
10. Covanis A, Skiadas K, Loli N, et al. Absence epilepsy: early prognostic signs. Seizure 1992;1:281-289
11. Hollander E, Schiffman E, Cohen B, et al. Signs of central nervous system dysfunction in obsessive-compulsive disorder. Arch Gen Psychiatry 1990; 47:27-32
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
13. Fyer MR, Frances AJ, Sullivan T, et al. Comorbidity of borderline personality disorder. Arch Gen Psychiatry 1988;45:348-352
14. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry 1988;45:111-119
15. Hollander E, Stein DJ, DeCaria CM, et al. Serotonergic sensitivity in borderline personality disorder: preliminary findings. Am J Psychiatry 1994; 151:277-280
16. Coccaro EF, Kavoussi RJ, Hauger RL, et al. Serotonin function and antiaggressive response to fluoxetine: a pilot study. Biol Psychiatry 1997;42: 546-552
17. Kavoussi R, Armstead P, Coccaro E. The neurobiology of impulsive aggression. Psychiatr Clin North Am 1997;20:395-403
18. Goldberg SG, Schulz SC, Schulz PM, et al. Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry 1986;43:680-686
19. Markovitz PJ, Calabrese JR, Schulz SC, et al. Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry 1991; 148:1064-1067
20. Kavoussi RJ, Liu J, Coccaro EF. An open trial of sertraline in borderline personality disordered patients with impulsive aggression. J Clin Psychiatry 1994;55:137-141
21. Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry 1997;54:1081-1088
22. Soloff PH, Cornelius J, George A, et al. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry 1993;50: 377-385
23. Kravitz HM, Fawcett J. Carbamazepine in the treatment of affective disorders. Med Sci Res 1987;15:1-8
24. Blumer D, Heibronn M, Himmelhoch J. Indications for carbamazepine in mental illness: atypical psychiatric disorder or temporal lobe syndrome? Compr Psychiatry 1988;29:108-122
25. Mattes JA. Comparative effectiveness of carbamazepine and propranolol for rage outbursts. J Neuropsychiatry Clin Neurosci 1990;2:159-164
26. Barratt ES, Kent TA, Bryant SG, et al. A controlled trial of phenytoin in impulsive aggression [letter]. J Clin Psychopharmacol 1991;11:388-389
27. Jacobsen FM. Low dose valproate: a new treatment for cyclothymia, mild rapid cycling disorders, and premenstrual syndrome. J Clin Psychiatry 1993;54:229-234
28. Pies R, Adler DA, Ehrenberg BL. Sleep disorders and depression with atypical features: response to valproate. J Clin Psychopharmacol 1989;9: 352-355
29. Fesler FA. Valproate in combat-related posttraumatic stress disorder. J Clin Psychiatry 1991;52:361-364
30. Giakas WJ, Seibyl JP, Mazure CM. Valproate in the treatment of temper outbursts [letter] J Clin Psychiatry 1990;51:525
31. Hasan MY, Sewell RDE, Nicholls PJ. Does the anticonvulsant agent sodium valproate display behaviorally selective anti-offensive activity? [abstract] J Pharm Pharmacol 1998;42(suppl):185
32. Keck PE Jr, McElroy SL, Friedman LM. Valproate and carbamazepine in the treatment of panic and posttraumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes. J Clin Psychopharmacol 1992;12 (suppl 1):36S-41S
33. Roy-Byrne PP, Ward NG, Donnelly PJ. Valproate in anxiety and withdrawal symptoms. J Clin Psychiatry 1989;50(3, suppl):44-48
34. Stein DJ, Simeon D, Frenkel M, et al. An open trial of valproate in borderline personality disorder. J Clin Psychiatry 1995;56:506-510
35. Hollander E, Margolin L, Wong CM, et al. Double-blind placebo-controlled trial of divalproex sodium in the treatment of borderline personality disorder. Presented at the 38th annual conference of the New Clinical Drug Evaluation Unit, June 11, 1998; Boca Raton, Fla
36. Porsolt RD. Serotonin: neurotransmitter "a la mode." Report on the Third International I.T.E.M.-LABO symposium on strategies in psychopharmacology: serotonin: animal models and clinical targets. Pharmacopsychiatry 1993;26:20-24